317 related articles for article (PubMed ID: 26842920)
41. Reference values for height and weight in Prader-Willi syndrome based on 315 patients.
Wollmann HA; Schultz U; Grauer ML; Ranke MB
Eur J Pediatr; 1998 Aug; 157(8):634-42. PubMed ID: 9727846
[TBL] [Abstract][Full Text] [Related]
42. Effect of growth hormone on height, weight, and body composition in Prader-Willi syndrome.
Davies PS; Evans S; Broomhead S; Clough H; Day JM; Laidlaw A; Barnes ND
Arch Dis Child; 1998 May; 78(5):474-6. PubMed ID: 9659098
[TBL] [Abstract][Full Text] [Related]
43. Circulating Levels of Nesfatin-1 and Spexin in Children with Prader-Willi Syndrome during Growth Hormone Treatment and Dietary Intervention.
Gajewska J; Szamotulska K; Klemarczyk W; Chełchowska M; Strucińska M; Ambroszkiewicz J
Nutrients; 2023 Mar; 15(5):. PubMed ID: 36904239
[TBL] [Abstract][Full Text] [Related]
44. Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial.
Bakker NE; Siemensma EP; Koopman C; Hokken-Koelega AC
Horm Res Paediatr; 2015; 83(5):321-31. PubMed ID: 25764996
[TBL] [Abstract][Full Text] [Related]
45. Thyroid hormone levels in children with Prader-Willi syndrome before and during growth hormone treatment.
Festen DA; Visser TJ; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2007 Sep; 67(3):449-56. PubMed ID: 17716335
[TBL] [Abstract][Full Text] [Related]
46. Longitudinal evaluation of sleep-disordered breathing in children with Prader-Willi Syndrome during 2 years of growth hormone therapy.
Al-Saleh S; Al-Naimi A; Hamilton J; Zweerink A; Iaboni A; Narang I
J Pediatr; 2013 Feb; 162(2):263-8.e1. PubMed ID: 22947651
[TBL] [Abstract][Full Text] [Related]
47. Body composition abnormalities in children with Prader-Willi syndrome and long-term effects of growth hormone therapy.
Eiholzer U; l'Allemand D; van der Sluis I; Steinert H; Gasser T; Ellis K
Horm Res; 2000; 53(4):200-6. PubMed ID: 11044804
[TBL] [Abstract][Full Text] [Related]
48. The growth hormone response to hexarelin in patients with Prader-Willi syndrome.
Cappa M; Raguso G; Palmiotto T; Faedda A; Gurreri F; Neri G; Deghenghi R; Loche S
J Endocrinol Invest; 1998 Sep; 21(8):501-5. PubMed ID: 9801990
[TBL] [Abstract][Full Text] [Related]
49. Short-term effects of growth hormone on sleep abnormalities in Prader-Willi syndrome.
Miller J; Silverstein J; Shuster J; Driscoll DJ; Wagner M
J Clin Endocrinol Metab; 2006 Feb; 91(2):413-7. PubMed ID: 16317059
[TBL] [Abstract][Full Text] [Related]
50. Prader-Willi syndrome: the care and treatment of infants, children, and adults.
Zipf WB
Adv Pediatr; 2004; 51():409-34. PubMed ID: 15366782
[TBL] [Abstract][Full Text] [Related]
51. Anthropometric characteristics of newborns with Prader-Willi syndrome.
Salvatoni A; Moretti A; Grugni G; Agosti M; Azzolini S; Bonaita V; Cianci P; Corica D; Crinò A; Delvecchio M; Ferraris S; Greggio NA; Iughetti L; Licenziati MR; Madeo SF; Nosetti L; Pajno R; Rutigliano I; Sacco M; Salvatore S; Scarano E; Trifirò G; Wasniewska M
Am J Med Genet A; 2019 Oct; 179(10):2067-2074. PubMed ID: 31361394
[TBL] [Abstract][Full Text] [Related]
52. Metabolic health profile in young adults with Prader-Willi syndrome: results of a 2-year randomized, placebo-controlled, crossover GH trial.
Kuppens RJ; Bakker NE; Siemensma EP; Donze SH; Stijnen T; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2017 Feb; 86(2):297-304. PubMed ID: 27689944
[TBL] [Abstract][Full Text] [Related]
53. Contributing factors of mortality in Prader-Willi syndrome.
Proffitt J; Osann K; McManus B; Kimonis VE; Heinemann J; Butler MG; Stevenson DA; Gold JA
Am J Med Genet A; 2019 Feb; 179(2):196-205. PubMed ID: 30569567
[TBL] [Abstract][Full Text] [Related]
54. Early manifestations of Prader-Willi syndrome: influence of growth hormone.
Eiholzer U; Schlumpf M; Nordmann Y; l'Allemand D
J Pediatr Endocrinol Metab; 2001; 14 Suppl 6():1441-4. PubMed ID: 11837497
[TBL] [Abstract][Full Text] [Related]
55. The GHRH + arginine stimulated pituitary GH secretion in children and adults with Prader-Willi syndrome shows age- and BMI-dependent and genotype-related differences.
Marostica E; Grugni G; De Nicolao G; Marazzi N; Crinò A; Cappa M; Sartorio A
Growth Horm IGF Res; 2013 Dec; 23(6):261-6. PubMed ID: 24090687
[TBL] [Abstract][Full Text] [Related]
56. Are sleep studies helpful in children with Prader-Willi syndrome prior to commencement of growth hormone therapy?
Vandeleur M; Davey MJ; Nixon GM
J Paediatr Child Health; 2013 Mar; 49(3):238-41. PubMed ID: 23438058
[TBL] [Abstract][Full Text] [Related]
57. Glucose homeostasis in Prader-Willi syndrome and potential implications of growth hormone therapy.
Zipf WB
Acta Paediatr Suppl; 1999 Dec; 88(433):115-7. PubMed ID: 10626560
[TBL] [Abstract][Full Text] [Related]
58. GH treatment reduces total ghrelin in Prader-Willi syndrome (PWS) and may confound ghrelin studies in young PWS children.
Hauffa BP; Petersenn S
Clin Endocrinol (Oxf); 2009 Jul; 71(1):155-6. PubMed ID: 19178506
[No Abstract] [Full Text] [Related]
59. Growth hormone treatment for adults with Prader-Willi syndrome: another point of view.
Hirsch HJ; Gross-Tsur V
Orphanet J Rare Dis; 2021 Aug; 16(1):337. PubMed ID: 34344408
[TBL] [Abstract][Full Text] [Related]
60. Association between foot growth and musculoskeletal loading in children with Prader-Willi syndrome before and during growth hormone treatment.
Eiholzer U; Meinhardt U; Gallo C; Schlumpf M; Rousson V; l'Allemand D
J Pediatr; 2009 Feb; 154(2):225-9. PubMed ID: 18822426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
